OncoMatch

OncoMatch/Clinical Trials/NCT05858814

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

Is NCT05858814 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies RC1012 for acute myeloid leukemia.

Phase 1/2RecruitingGuangdong Ruishun Biotech Co., LtdNCT05858814Data as of May 2026

Treatment: RC1012To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: allogeneic hematopoietic stem cell transplant

The subject has received an allogeneic HSCT within 60-100 days

Cannot have received: organ transplant

Exception: except for HSCT

Persons who have previously received an organ transplant or are preparing to receive an organ transplant (except for HSCT).

Cannot have received: maintenance therapy after HSCT

Subject who has received other maintenance therapy drugs after HSCT or who wish to receive other maintenance therapy.

Lab requirements

Blood counts

hemoglobin ≥ 80 g/L or maintained by transfusion; ANC ≥ 1.5 x 10^9/L; platelet count ≥ 50 x 10^9/L or maintained by transfusion; INR ≤ 1.5x ULN; APTT ≤ 1.5x ULN

Kidney function

serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 60 ml/min

Liver function

AST ≤ 3x ULN; ALT ≤ 3x ULN; total bilirubin ≤ 1.5x ULN (≤ 3.0x ULN for Gilbert-Meulengracht syndrome, direct bilirubin ≤ 1.5x ULN)

Cardiac function

LVEF ≥ 45%

With appropriate organ function: AST ≤ 3x ULN; ALT ≤ 3x ULN; total bilirubin ≤ 1.5x ULN, unless the patient has documented Gilbert syndrome. Patients with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0x ULN and direct bilirubin ≤ 1.5x ULN may be included; serum creatinine ≤ 1.5x ULN or a creatinine clearance ≥ 60 ml/min; hemoglobin ≥ 80 g/L or hemoglobin maintained at that level following transfusion; INR ≤ 1.5x ULN and APTT ≤ 1.5x ULN; ANC ≥ 1.5 x 10^9/L; platelet count ≥ 50 x 10^9/L or maintained by transfusion; LVEF ≥ 45%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify